Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-255-4 | CAS number: 31775-89-0
Additional physico-chemical information
Administrative data
- Endpoint:
- other: Stability, homogeneity and concentration during dosing period of 28-day study
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- Start: 09 October 2008. Completion: 16 March 2009
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study conducted in compliance with agreed protocols, with no or minor deviations from standard test guidelines and/or minor methodological deficiencies, which do not affect the quality of relevant results.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 009
- Report date:
- 2009
Materials and methods
Test guideline
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- The purpose of this study is to determine the stability of the test substance during the dosing period, and homogeneity, stability and concentration of the test substance in formulation in "Twenty-Eight-Day Repeated-Dose Oral Toxicity Study of KarenzMT (Mixture of PEMB andPE3MB) in Rats" (Study Code: BII-0908).
- GLP compliance:
- yes
- Remarks:
- GLP statement signed March 16 2009
Test material
- Reference substance name:
- 3-{[(3R)-3-sulfanylbutanoyl]oxy}-2,2-bis({[(3R)-3-sulfanylbutanoyl]oxy}methyl)propyl (3R)-3-sulfanylbutanoate; 3-{[(3R)-3-sulfanylbutanoyl]oxy}-2,2-bis({[(3S)-3-sulfanylbutanoyl]oxy}methyl)propyl (3R)-3-sulfanylbutanoate; 3-{[(3R)-3-sulfanylbutanoyl]oxy}-2-({[(3R)-3-sulfanylbutanoyl]oxy}methyl)-2-({[(3S)-3-sulfanylbutanoyl]oxy}methyl)propyl (3R)-3-sulfanylbutanoate; 3-{[(3S)-3-sulfanylbutanoyl]oxy}-2,2-bis({[(3S)-3-sulfanylbutanoyl]oxy}methyl)propyl (3R)-3-sulfanylbutanoate; 3-{[(3S)-3-sulfanylbutanoyl]oxy}-2,2-bis({[(3S)-3-sulfanylbutanoyl]oxy}methyl)propyl (3S)-3-sulfanylbutanoate
- EC Number:
- 700-255-4
- Cas Number:
- 31775-89-0
- Molecular formula:
- C21H36O8S4
- IUPAC Name:
- 3-{[(3R)-3-sulfanylbutanoyl]oxy}-2,2-bis({[(3R)-3-sulfanylbutanoyl]oxy}methyl)propyl (3R)-3-sulfanylbutanoate; 3-{[(3R)-3-sulfanylbutanoyl]oxy}-2,2-bis({[(3S)-3-sulfanylbutanoyl]oxy}methyl)propyl (3R)-3-sulfanylbutanoate; 3-{[(3R)-3-sulfanylbutanoyl]oxy}-2-({[(3R)-3-sulfanylbutanoyl]oxy}methyl)-2-({[(3S)-3-sulfanylbutanoyl]oxy}methyl)propyl (3R)-3-sulfanylbutanoate; 3-{[(3S)-3-sulfanylbutanoyl]oxy}-2,2-bis({[(3S)-3-sulfanylbutanoyl]oxy}methyl)propyl (3R)-3-sulfanylbutanoate; 3-{[(3S)-3-sulfanylbutanoyl]oxy}-2,2-bis({[(3S)-3-sulfanylbutanoyl]oxy}methyl)propyl (3S)-3-sulfanylbutanoate
- Details on test material:
- - Name of test material (as cited in study report): Karenz MT (Mixture of PEMB and PE3MB)
- Substance type: Monoconstituent
- Physical state: Yellow, clear liquid
- Analytical purity: 95.8 % (PEMB: 81.7%, PE3MB 14.1%)
- Lot/batch No.: PE080805
- Expiration date of the lot/batch: not stated in the report
- Storage condition of test material: Dark storage place at room temperature and avoided contacting with oxidizing agent.
Constituent 1
Results and discussion
- Results:
- The test substance (KarenzMT (Mixture of PEMB and PE3MB)) was stable during the dosing period of subject study (Study Code: B11-0908).The test substance in 10.0 and 0.25 w/v% formulations was stable for 8 days after preparation at cold and dark place and showed good homogeneity. The concentration oftest substance in 10.0, 1.5 and 0.25 w/v% dose formulations for subject study was acceptable level.
Any other information on results incl. tables
Stability Analysis of the Test Substance
IR spectrum of test substance provided by the sponsor was identical with that measured before dosing period for subject study (Figure 1). There were no differences in the IR spectra between before and after dosing period (Figures 1,2).
Homogeneity, Stability and Concentration Analyses of the Test Substance Formulation
1) Homogeneity and Stability Analyses
The results of homogeneity and stability analyses of the test substance formulation are shown in Table 1.
(I) Homogeneity Analysis CV of 10.0 and 0.25 w/v% formulations were 0.6 and 1.0%, respectively. The results satisfied criteria for judgment.
(2) Stability Analysis
a) 10.0 w/v% Formulation
At immediately after preparation, R.N. were 101 to 102%.
At 3 days after preparation, R.N. was 100%, and R.P. was 98.0%.
At 9 days after preparation, R.N. was 101 %, and R.P. was 99.0%.
All the results of R.N. and R.P. satisfied criteria for judgment.
b) 0.25 w/v% Formulation
At immediately after preparation, R.N. were 102 to 104%.
At 3 days after preparation, R.N. was 102%, and R.P. was 99.6%.
At 9 days after preparation, R.N. was 102%, and R.P. was 100%.
All the results of R.N. and R.P. satisfied criteria for judgment.
2) Concentration Analysis
The results of concentration analysis of the test substance formulation are shown in Table 2. R.N. of 10.0, 1.5 and 0.25 w/v% dose fonnulations were 99.1 to 101%. All the results satisfied criteria for judgment.
Applicant's summary and conclusion
- Conclusions:
- The test substance was stable in formulations during the dosing period of subject study.The test substance in 10.0 and 0.25 % (w/v) formulations was stable for 8 days after preparation when stored at a cold and dark place and showed good homogeneity. The concentration of test substance in 10.0, 1.5 and 0.25 % (w/v) dose formulations for subject study was at acceptable level.
- Executive summary:
The purpose of this study is to determine the stability of the test substance in formulation during the dosing period, and homogeneity, stability and concentration of the test substance in formulation in "Twenty-Eight-Day Repeated-Dose Oral Toxicity Study of KarenzMT (Mixture of PEMB and PE3MB) in Rats" (Study Code: BII-0908).
The test substance was stable in formulation during the dosing period of subject study. The test substance in 10.0 and 0.25 % (w/v) formulations was stable for 8 days after preparation when stored at a cold and dark place and showed good homogeneity. The concentration of test substance in 10.0, 1.5 and 0.25 % (w/v) dose formulations for subject study was at acceptable level.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
